<DOC>
	<DOCNO>NCT02118831</DOCNO>
	<brief_summary>Comparable data bevacizumab aflibercept lack , study compare systemic level ranibizumab , bevacizumab , aflibercept relative effect circulate vascular endothelial growth factor . In present prospective study , investigator evaluate serum drug level plasma free vascular endothelial growth factor ( VEGF ) level patient neovascular age-related macular degeneration follow intravitreal injection ranibizumab , bevacizumab aflibercept .</brief_summary>
	<brief_title>Systemic Pharmacokinetics Following Intravitreal Injections Anti-VEGF</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent participation study Subjects diagnosis neovascular agerelated macular degeneration , diabetic macular edema , retinal vein occlusion either treatment na√Øve 4 month prior intravitreal antivascular endothelial growth factor injection Subjects unwilling receive 3 monthly injection antivascular endothelial growth factor initial therapy Subjects may need receive systemic antivascular endothelial growth factor oncology past year Subjects history another ocular disease neovascular agerelated macular degeneration , diabetic macular edema , retinal vein occlusion Subjects history vitrectomy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>macular degeneration</keyword>
	<keyword>diabetic macular edema</keyword>
	<keyword>vein occlusion</keyword>
	<keyword>vascular endothelial growth factor</keyword>
</DOC>